The Paul-Bunnell heterophile antibody determinant in Epstein-Barr virus-associated disease

Roberto Patarca-Montero, Mary Ann Fletcher

Research output: Contribution to journalArticle

Abstract

Reactivation of latent herpes viruses (notably Epstein-Barr virus, human herpesvirus-6) is commonly seen in chronic fatigue syndrome and it is believed to contribute to symptom perpetuation. Epstein-Barr virus (EBV), which was first isolated by Epstein, Barr and Achong (1964) from a cultured Burkitt's lymphoma lymphoblast cell line, is the etiological agent for infectious mononucleosis (IM), polyclonal and oligoclonal lymphomas associated with primary and acquired immunodeficiencies, and the complications of X-linked lymphopro-liferative syndrome (XLP) (Cantani and Mastrantoni, 1989; Englund, 1988; Ernberg et al., 1990; Jones and Straus, 1987; Okano et al., 1988; Purtilo, 1987; Purtilo et al., 1981; Rowe et al., 1986; Saemundsen et al., 1981) and nasopharyngeal cancer (Pearson et al., 1984). Furthermore, people who have had IM have higher rates of subsequent development of malignant lymphoproliferative disorders (Abo et al., 1982; Snydman et al., 1982) and Hodgkin's disease (Green et al., 1979; Mueller, 1987; Poppema et al., 1985; Weiss et al., 1989), while patients with XLP have a higher incidence of non-Hodgkin's malignant lymphoma (Harrington et al., 1987). The precise role of EBV in these diseases or in CFS is not well understood. Nonetheless, it is known that EBV infection triggers the formation of heterophile antibodies that, for many decades, have formed the basis for serologic diagnosis of IM. In this review, we discuss the discovery, species variation, and structure of the erythrocyte membrane-associated Paul-Bunnell (PB) heterophile antibody determinant, its implications to IM diagnosis, and its potential contribution to defective immune surveillance, such as that seen in chronic fatigue syndrome.

Original languageEnglish
Pages (from-to)51-86
Number of pages36
JournalJournal of Chronic Fatigue Syndrome
Volume10
Issue number3-4
DOIs
StatePublished - Nov 6 2002
Externally publishedYes

Fingerprint

Heterophile Antibodies
Infectious Mononucleosis
Virus Diseases
Human Herpesvirus 4
Chronic Fatigue Syndrome
Lymphoma
Nasopharyngeal Neoplasms
Human Herpesvirus 6
Epstein-Barr Virus Infections
Burkitt Lymphoma
Lymphoproliferative Disorders
Erythrocyte Membrane
Hodgkin Disease
Non-Hodgkin's Lymphoma
Viruses
Cell Line
Incidence

Keywords

  • Chronic fatigue syndrome
  • Epstein-Barr virus
  • Hodgkin's disease
  • Infectious mononucleosis
  • T-cell proliferation

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology

Cite this

The Paul-Bunnell heterophile antibody determinant in Epstein-Barr virus-associated disease. / Patarca-Montero, Roberto; Fletcher, Mary Ann.

In: Journal of Chronic Fatigue Syndrome, Vol. 10, No. 3-4, 06.11.2002, p. 51-86.

Research output: Contribution to journalArticle

Patarca-Montero, Roberto ; Fletcher, Mary Ann. / The Paul-Bunnell heterophile antibody determinant in Epstein-Barr virus-associated disease. In: Journal of Chronic Fatigue Syndrome. 2002 ; Vol. 10, No. 3-4. pp. 51-86.
@article{906bececfe3f4b07b53d8a54e6689fcf,
title = "The Paul-Bunnell heterophile antibody determinant in Epstein-Barr virus-associated disease",
abstract = "Reactivation of latent herpes viruses (notably Epstein-Barr virus, human herpesvirus-6) is commonly seen in chronic fatigue syndrome and it is believed to contribute to symptom perpetuation. Epstein-Barr virus (EBV), which was first isolated by Epstein, Barr and Achong (1964) from a cultured Burkitt's lymphoma lymphoblast cell line, is the etiological agent for infectious mononucleosis (IM), polyclonal and oligoclonal lymphomas associated with primary and acquired immunodeficiencies, and the complications of X-linked lymphopro-liferative syndrome (XLP) (Cantani and Mastrantoni, 1989; Englund, 1988; Ernberg et al., 1990; Jones and Straus, 1987; Okano et al., 1988; Purtilo, 1987; Purtilo et al., 1981; Rowe et al., 1986; Saemundsen et al., 1981) and nasopharyngeal cancer (Pearson et al., 1984). Furthermore, people who have had IM have higher rates of subsequent development of malignant lymphoproliferative disorders (Abo et al., 1982; Snydman et al., 1982) and Hodgkin's disease (Green et al., 1979; Mueller, 1987; Poppema et al., 1985; Weiss et al., 1989), while patients with XLP have a higher incidence of non-Hodgkin's malignant lymphoma (Harrington et al., 1987). The precise role of EBV in these diseases or in CFS is not well understood. Nonetheless, it is known that EBV infection triggers the formation of heterophile antibodies that, for many decades, have formed the basis for serologic diagnosis of IM. In this review, we discuss the discovery, species variation, and structure of the erythrocyte membrane-associated Paul-Bunnell (PB) heterophile antibody determinant, its implications to IM diagnosis, and its potential contribution to defective immune surveillance, such as that seen in chronic fatigue syndrome.",
keywords = "Chronic fatigue syndrome, Epstein-Barr virus, Hodgkin's disease, Infectious mononucleosis, T-cell proliferation",
author = "Roberto Patarca-Montero and Fletcher, {Mary Ann}",
year = "2002",
month = "11",
day = "6",
doi = "10.1300/J092v10n03_06",
language = "English",
volume = "10",
pages = "51--86",
journal = "Journal of Chronic Fatigue Syndrome",
issn = "1057-3321",
publisher = "The Haworth Medical Press",
number = "3-4",

}

TY - JOUR

T1 - The Paul-Bunnell heterophile antibody determinant in Epstein-Barr virus-associated disease

AU - Patarca-Montero, Roberto

AU - Fletcher, Mary Ann

PY - 2002/11/6

Y1 - 2002/11/6

N2 - Reactivation of latent herpes viruses (notably Epstein-Barr virus, human herpesvirus-6) is commonly seen in chronic fatigue syndrome and it is believed to contribute to symptom perpetuation. Epstein-Barr virus (EBV), which was first isolated by Epstein, Barr and Achong (1964) from a cultured Burkitt's lymphoma lymphoblast cell line, is the etiological agent for infectious mononucleosis (IM), polyclonal and oligoclonal lymphomas associated with primary and acquired immunodeficiencies, and the complications of X-linked lymphopro-liferative syndrome (XLP) (Cantani and Mastrantoni, 1989; Englund, 1988; Ernberg et al., 1990; Jones and Straus, 1987; Okano et al., 1988; Purtilo, 1987; Purtilo et al., 1981; Rowe et al., 1986; Saemundsen et al., 1981) and nasopharyngeal cancer (Pearson et al., 1984). Furthermore, people who have had IM have higher rates of subsequent development of malignant lymphoproliferative disorders (Abo et al., 1982; Snydman et al., 1982) and Hodgkin's disease (Green et al., 1979; Mueller, 1987; Poppema et al., 1985; Weiss et al., 1989), while patients with XLP have a higher incidence of non-Hodgkin's malignant lymphoma (Harrington et al., 1987). The precise role of EBV in these diseases or in CFS is not well understood. Nonetheless, it is known that EBV infection triggers the formation of heterophile antibodies that, for many decades, have formed the basis for serologic diagnosis of IM. In this review, we discuss the discovery, species variation, and structure of the erythrocyte membrane-associated Paul-Bunnell (PB) heterophile antibody determinant, its implications to IM diagnosis, and its potential contribution to defective immune surveillance, such as that seen in chronic fatigue syndrome.

AB - Reactivation of latent herpes viruses (notably Epstein-Barr virus, human herpesvirus-6) is commonly seen in chronic fatigue syndrome and it is believed to contribute to symptom perpetuation. Epstein-Barr virus (EBV), which was first isolated by Epstein, Barr and Achong (1964) from a cultured Burkitt's lymphoma lymphoblast cell line, is the etiological agent for infectious mononucleosis (IM), polyclonal and oligoclonal lymphomas associated with primary and acquired immunodeficiencies, and the complications of X-linked lymphopro-liferative syndrome (XLP) (Cantani and Mastrantoni, 1989; Englund, 1988; Ernberg et al., 1990; Jones and Straus, 1987; Okano et al., 1988; Purtilo, 1987; Purtilo et al., 1981; Rowe et al., 1986; Saemundsen et al., 1981) and nasopharyngeal cancer (Pearson et al., 1984). Furthermore, people who have had IM have higher rates of subsequent development of malignant lymphoproliferative disorders (Abo et al., 1982; Snydman et al., 1982) and Hodgkin's disease (Green et al., 1979; Mueller, 1987; Poppema et al., 1985; Weiss et al., 1989), while patients with XLP have a higher incidence of non-Hodgkin's malignant lymphoma (Harrington et al., 1987). The precise role of EBV in these diseases or in CFS is not well understood. Nonetheless, it is known that EBV infection triggers the formation of heterophile antibodies that, for many decades, have formed the basis for serologic diagnosis of IM. In this review, we discuss the discovery, species variation, and structure of the erythrocyte membrane-associated Paul-Bunnell (PB) heterophile antibody determinant, its implications to IM diagnosis, and its potential contribution to defective immune surveillance, such as that seen in chronic fatigue syndrome.

KW - Chronic fatigue syndrome

KW - Epstein-Barr virus

KW - Hodgkin's disease

KW - Infectious mononucleosis

KW - T-cell proliferation

UR - http://www.scopus.com/inward/record.url?scp=0036406789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036406789&partnerID=8YFLogxK

U2 - 10.1300/J092v10n03_06

DO - 10.1300/J092v10n03_06

M3 - Article

AN - SCOPUS:0036406789

VL - 10

SP - 51

EP - 86

JO - Journal of Chronic Fatigue Syndrome

JF - Journal of Chronic Fatigue Syndrome

SN - 1057-3321

IS - 3-4

ER -